SKB BIO-B (06990): The core product sac-TMT will announce research results at the 2024 European Oncology Congress.

SKB BIO-B (06990) announced that the company will present the following research results of its anti-TROP2 ADC sacituzumab govitecan (sac-TMT, formerly known as SKB264/MK-2870) at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain from September 13-17, 2024: 1. The efficacy and safety of sacituzumab govitecan (sac-TMT) in combination with pembrolizumab (Keytruda) for patients with recurrent or metastatic cervical cancer (CC) will be presented in a mini oral presentation session on September 15, 2024, from 14:55 to 15:00 (Presentation ID: 716MO). 2. The safety and efficacy of sacituzumab govitecan (sac-TMT) monotherapy in a phase 2 study for patients with previously treated advanced endometrial cancer (EC) and ovarian cancer (OC) will be presented in a mini oral presentation session on September 15, 2024, from 14:50 to 14:55 (Presentation ID: 715MO). 3. An exploratory analysis of patients who have received or not received PD-(L)1 inhibitors in the phase 3 study (OptiTROP-Breast01) comparing sacituzumab govitecan (sac-TMT) with chemotherapy for previously treated advanced triple-negative breast cancer (TNBC) patients will be presented as a poster on September 16, 2024 (Poster ID: 386P). The abstracts of the above studies were published on the official website of the ESMO Congress on September 9, 2024.